Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: A double-blind, placebo-controlled trial

Antiviral Therapy

Volumn 12, Issue 3, 2007, Pages 345-353

  Chan, Henry Lik Yuen ^a   Wang, Hao ^b   Niu, Junqi ^c   Chim, Angel Mei Ling ^a   Sung, Joseph Jao Yiu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Beijing People's Hospital   (China)

^c THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PLACEBO; VIRUS DNA;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ACUTE APPENDICITIS; ADULT; AGED; ARTICLE; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DUODENAL ULCER BLEEDING; DYSPEPSIA; FEMALE; FRACTURE; GENOTYPE; HALLUCINATION; HEADACHE; HEPATITIS B; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; INTERVERTEBRAL DISK DISEASE; LIVER BIOPSY; LIVER CELL CARCINOMA; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NASOPHARYNX CARCINOMA; NEPHROLITHIASIS; NEUTROPHIL COUNT; PATIENT ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SIDE EFFECT; SORE THROAT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; CHINA; DNA, VIRAL; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; ENDPOINT DETERMINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HONG KONG; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34249090519     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996; 38 Suppl 2:S18-S23.
2. Chan HLY, Hui Y, Leung NWY, Ching JYL, Chan FKL, Sung JJY. Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus (HBV) infected patients. Am J Gastroenterol 2000; 95:3547-3551.
3. Sung JJY, Chan HLY, Wong ML, et al. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J Viral Hepat 2002; 9:229-234.
4. Chu CJ, Hussain M, Lok ASF. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2003; 36:1408-1415.
5. Chan HLY, Tsang SWC, Liew CT, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97:406-412.
6. Chan HLY, Wong ML, Hui AY, Hung LCT, Chan FKL, Sung JJY. Use of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in chronic hepatitis B. J Clin Microbiol 2003; 41:4693-4695.
7. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135:759-768.
8. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35:1522-1527.
9. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-68.
10. Dienstag J, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-1263.
11. Van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52:420-424.
12. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32:803-806.
13. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serological response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37:748-755.
14. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29:889-896.
15. Gaia S, Marzano A, Smedile A, et al. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2004; 20:281-287.
16. Fung SK, Wong F, Hussain M, Lok ASF. Sustained response after 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11:432-438.
17. Rizzetto M, Tassopoulos NC, Goldin RD, et al. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol 2005; 42:173-179.
18. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy during starting with lamivudine. Hepatology 2005; 42:121-129.
19. Chan HLY, Leung NWY, Lau TCM, Wong ML, Sung JJY. Comparison of three different sensitive assays for hepatitis B virus (HBV) DNA in monitoring response of anti-viral therapy. J Clin Microbiol 2000; 38:3205-3208.
20. Loeb KR, Jerome KR, Goddard J, Huang ML, Cent A, Corey L. High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. Hepatology 2000; 32:626-629.
21. Chan HLY, Chui AKK, Lau WY, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68:182-187.
22. Lok AS, Zoulim F, Locarnini S, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002; 40:3729-3734.
23. Chan HLY, Leung NWY, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: Comparing pegylated interferon-α2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142:240-250.
24. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographical origin of hepatitis B virus - large-scaled analysis using a new genotyping method. J Infect Dis 1997; 175:1285-1293.
25. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34:617-624.
26. Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ. Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody-positive patients. Hepatology 1987; 7:20-23.
27. Yuen MF, Salbon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34:785-791.
28. Sung JJY, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128:1890-1897.
29. Chan HLY, Wong VWS, Hui AY, et al. Long-term lamivudine treatment is associated with good maintained response in severe acute exacerbation of hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2006; 11:465-471.
30. Hadziyannis S, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352:2673-2681.
31. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42:121-129.
32. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.